<code id='E4AB4EA443'></code><style id='E4AB4EA443'></style>
    • <acronym id='E4AB4EA443'></acronym>
      <center id='E4AB4EA443'><center id='E4AB4EA443'><tfoot id='E4AB4EA443'></tfoot></center><abbr id='E4AB4EA443'><dir id='E4AB4EA443'><tfoot id='E4AB4EA443'></tfoot><noframes id='E4AB4EA443'>

    • <optgroup id='E4AB4EA443'><strike id='E4AB4EA443'><sup id='E4AB4EA443'></sup></strike><code id='E4AB4EA443'></code></optgroup>
        1. <b id='E4AB4EA443'><label id='E4AB4EA443'><select id='E4AB4EA443'><dt id='E4AB4EA443'><span id='E4AB4EA443'></span></dt></select></label></b><u id='E4AB4EA443'></u>
          <i id='E4AB4EA443'><strike id='E4AB4EA443'><tt id='E4AB4EA443'><pre id='E4AB4EA443'></pre></tt></strike></i>

          Home / hotspot / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:279
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In